Babatin MA, et al. - During this study, experts contemplated the efficacy and safety of sofosbuvir (SOF) in combination with either simeprevir (SMV) or daclatasvir (DCV) in genotype (GT)4-infected patients. Results demonstrated that all patients achieved sustained virologic response 12 (100%). The occurrence of adverse events was reported in 32% of patients. However, none of the patients discontinued treatment. Findings ascertained that SMV/SOF or DCV/SOF combinations were safe and highly effective in hepatitis C virus (HCV)-GT4 treatment. It was noted that cirrhosis and failure of prior interferon-based treatment did not exert an impact on the treatment response.